The Paradigm Shift from Traditional Scientific Platforms to Integrated Communications Plans
In the rapidly evolving biopharma landscape, the approach to scientific communications is undergoing a significant transformation. The shift from traditional scientific platforms to integrated communications plans (ICPs) is becoming increasingly crucial for ensuring cohesive and impactful messaging. This article delves into the components, implementation, and benefits of an ICP tailored for the biopharma industry, addressing the challenges of fragmented messaging and the need for a unified communication strategy...
Read MoreTop Stories
The Paradigm Shift from Traditional Scientific
In the rapidly evolving biopharma landscape, the approach to...
It’s Never Too Soon: How and When to
Engagement with Medical Affairs is critical at every...
Celebrating Health Literacy Month 2024:
October is Health Literacy Month, a reminder of the...
Filter
Promoting Diversity and Inclusion in Clinical Trials – New England Journal of Medicine’s New Policy
Read this update on how the New England Journal of Medicine is trying to promote...
MedTech Summit 2021: Understanding Post Market Clinical Follow Up (PCMF)
An ideal PMCF plan, with reference to MDCG 2020-7, presents the general and specific methods...
Bringing New Devices to Market under the EU MDR
With the MDR coming into effect, the manufacturers should plan and construct their strategy to...
Pharma, Physician, and Patient Pain Points Regarding Clinical Trials
Pharma, physicians, and patients consistently face challenges related to clinical trials. Here's a quick look...
Clinical Trial Summaries – What Are They and Why Do They Matter for Pharma?
A majority of patients feel lay summaries for clinical trials are very important and won’t...
Digital Scientific Content: Stakeholder Perspectives
What do the different relevant stakeholder groups truly expect from pharma-generated scientific content?...